A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety and Tolerability of MT 7117 in Adults and Adolescents with Erythropoietic Protoporphyria or X Linked Protoporphyria

    Project: Other project

    Project Details

    StatusActive
    Effective start/end date9/17/20 → 9/16/25

    Funding

    • Mitsubishi Tanabe Pharma: $73,282.11